Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Screening Criteria:~1. Males or females ≥ 12 years of age with a documented history of SCD~2. Patients with symptomatic PAH associated with shortness of breath~3. Patients with tricuspid regurgitation jet (TRJ) velocity of \> 2.9 m/sec based on echo/Doppler conducted within 6 months prior to randomization and not during SCD crisis~4. Signed written informed consent is obtained from the patient or patient's parent/legal representative prior to initiation of any study related procedure~Inclusion Criteria:~1. Patients with hemoglobin (Hb) SS or Hb S/β0 genotype and with Hb A ≤ 10%~2. Six-minute walk test (6MWT) distance ≥ 150 m and ≤ 450 m~3. PAH confirmed by right heart catheterization (RHC) performed at the study site within 3 months of the randomization visit and defined as:~   * Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg~  * Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg measured by RHC or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg measured by left heart catheterization, if PCWP measurement is not reliable~  * Pulmonary vascular resistance (PVR) at rest ≥ 160 dyn.sec/cm5~4. Women of childbearing potential must have a negative result on their serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination~Exclusion Criteria:~1. Left ventricular ejection fraction \< 40% (echo/Doppler)~2. Systolic blood pressure \< 85 mmHg~3. Uncontrolled hypertension with systolic blood pressure \>160 mmHg and/or diastolic blood pressure \> 100 mmHg~4. Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) \< 0.5~5. Total lung capacity (TLC) \< 50% of normal predicted value~6. Significant cardiac disease: ischemic, valvular, constrictive~7. Hemoglobin concentration \< 6.0 g/dL at the time of randomization~8. Acute liver disease~9. Evidence of cirrhosis or portal hypertension on a liver ultrasound or biopsy~10. ALT ≥ 2 times upper limit of normal (ULN) and/or albumin \< 2.8 g/dL~11. Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT), e.g., angina pectoris, intermittent claudication, symptomatic hip osteonecrosis~12. Vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 2 weeks of randomization or more than 12 VOC and/or ACS within the last 12 months~13. Blood transfusion within 4 weeks prior to randomization~14. Illness with a life expectancy shorter than 6 months~15. HIV with opportunistic infection~16. Psychotic, addictive, or other disorder limiting the ability to provide informed consent or to comply with study requirements~17. Pregnant or lactating women~18. Recently started (\< 8 weeks prior to randomization) or planned, exercise-based cardio-pulmonary rehabilitation program~19. Bone marrow transplantation~20. Treatment or planned treatment with another investigational drug within 3 months prior to randomization~21. Treatment for pulmonary hypertension with an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 3 months prior to randomization or with L-arginine within 1 week prior to randomization~22. Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus), sirolimus, fluconazole, amiodarone, miconazole and glibenclamide (glyburide) within 1 week prior to randomization~23. Known hypersensitivity to bosentan or any of its excipients

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).